Sleep Apnea Linked to Diabetic Retinopathy in Type 2 Diabetes

This article originally appeared here.
Share this content:
Sleep Apnea Linked to Diabetic Retinopathy in Type 2 Diabetes
Sleep Apnea Linked to Diabetic Retinopathy in Type 2 Diabetes

WEDNESDAY, June 14, 2017 (HealthDay News) -- For patients with type 2 diabetes, obstructive sleep apnea (OSA) is associated with sight-threatening diabetic retinopathy (STDR) and with progression to pre-/proliferative DR, according to a study published online June 8 in the American Journal of Respiratory and Critical Care Medicine.

Quratul A. Altaf, from the University of Birmingham in the United Kingdom, and colleagues examined the impact of OSA on DR in a longitudinal study. Data were included for 230 patients from diabetes clinics in two U.K. hospitals.

The researchers found that the prevalence of STDR and OSA were 36.1 and 63.9 percent, respectively. The prevalence of STDR was significantly higher in patients with versus those without OSA (42.9 versus 24.1 percent). OSA remained significantly independently associated with STDR after adjustment for confounders (odds ratio, 2.3). Patients with versus those without OSA were significantly more likely to develop pre-/proliferative DR after a median follow-up of 43.0 months (18.4 versus 6.1 percent); OSA remained a significant independent predictor of progression to pre-/proliferative DR after adjustment for confounders (odds ratio, 5.2). The likelihood of developing pre-/proliferative DR was reduced for patients who received continuous positive airway pressure treatment.

"OSA is associated with STDR in patients with T2D," the authors write. "Interventional studies are needed to assess the impact of OSA treatment on STDR."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »